TCR2 Therapeutics Inc. Stock News

TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni

TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni

CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data fr

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suf

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffe

Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) have been given an average recommendation of Buy by the eleven ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that []

Analysts expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) to post ($0.75) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for TCR2 Therapeutics earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.86). TCR2 Therapeutics posted earnings per share of ($0.55) during the same quarter last year, which would []

In last trading session, TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw 0.68 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $5.01 trading at -$0.22 or -4.21% at ring of the bell on the day assigns it a market valuation of $196.34M. That closing price of TCRRs stock is TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares Dropped -4.39% In A Week. Can It Continue Rising? Read More »

Credit Suisse AG trimmed its position in shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) by 45.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,245 shares of the companys stock after selling 11,124 shares during the period. Credit Suisse AGs holdings in []

Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More

During the last session, TCR2 Therapeutics Inc. (NASDAQ:TCRR)s traded shares were 0.34 million. At the end of the trading day, the stocks price was $5.63, reflecting an intraday gain of 1.08% or $0.06. The 52-week high for the TCRR share is $35.86, that puts it down -536.94 from that peak though still a striking 6.75% TCR2 Therapeutics Inc. (NASDAQ: TCRR) Is Up 6.75% From Its 52-Week Low; YTD, It Is Down -81.80% What To Do Now Read More »